Replies to Post #6200 onBioPharm Asia, Inc (fka BFAR)

Replies to #6200 on BioPharm Asia, Inc (fka BFAR)

07/13/12 4:52 PM

#6202 RE: VeryHolyGuy #6200

Hey very below I have a 2 paragraph quote where the SEC is informed by a company about late filing and other matters. I would like you to note how auditors are relevant to this process, but at the same time THE NEED FOR AN ATTORNEY TO ALSO REVIEW THE FILING OF THE FORMS.

I have already stressed that if BFAR issues a PR informing that they have hired a law firm to represent them in the USA, that would be the first indication that something is brewing. Until that happens nothing is going to happen!

The primary reason for the delay is the finalization of the prior audit period ending December 31, 2009 which requires the previous company auditor and the Company's new auditor to reconcile the prior audit (2008) with the current audit period (2009). Both auditors and the Company's lawyers have been busy with completing 10K's and audits for other reporting Companies that have the March 31 filing deadline. The 2009 audit dictates every other number going forward and must be finalized before the following periods can be finalized and filed. The Company is confident that all reports will be filed in the next 15 calendar days.

The reports contain the 2009 10K and 2010 10Q's for quarters 1, 2 and 3 and the 10K for 2010. Once signed off by the Company's Auditors and filed and accepted with the SEC, the Company will have fully satisfied its reporting requirements and the Caveat Emptor status should be removed. Once all filings are complete, the Company intends to re-apply to re-list on the OTCBB and is committed to maintaining a fully reporting status to insure a higher level of transparency.